Media and News
Rochester, NY: PharmaNova partners with diagnostics and device company, Rochester Innovations
PharmaNova Inc. announced today that it has entered into a collaboration with Rochester Innovations Inc., a specialty diagnostics and devices company of Rochester, NY.
The companies will collaborate on the development of products combining Rochester Innovation’s diagnostic, drug delivery and dispensing technologies with PharmaNova’s nanoparticle technology and formulation expertise. Their goal is to develop new products and intellectual property in the field of handheld personal diagnostics, and drug-device combinations for the precisely- metered delivery of liquid and semi-solid formulations for oral, topical, and transdermal medications. PharmaNova will develop these products through appropriate levels of proof of concept and, through its worldwide affiliations will facilitate commercialization both directly and/or through licensing arrangements with regional partners.
PharmaNova President Rodney Brown said “The collaboration with Rochester Innovations is a perfect complement to our business model for creating value by improving and enhancing pharmaceuticals. This partnership adds a further dimension-- and value -- to our growing portfolio. We are privileged to have Dr. Youti Kuo and Rochester Innovations working so closely and creatively with us.” Dr. Kuo, President of Rochester Innovations said “The development of new patents is fundamental to the success of technology-based companies and our joint development of intellectual property will provide a powerful competitive edge. The collaboration between PharmaNova and Rochester Innovations is a great model for generating value from complementary, convergent technologies and accelerating the development of truly innovative products.
PharmaNova Inc. is a privately held, specialty drug development company founded on the re-purposing and enhancement of known drugs using proprietary nanoparticle and other complementary formulation technologies. PharmaNova specializes in low risk, fast to market products and generates revenue from partnering and licensing strategies with commercialization partners worldwide. The company’s current focus is on extraordinary value products in Women’s Health and adjacent areas, including a non-hormonal treatment for hot flashes associated with menopause, and for vasomotor symptoms secondary to the treatment of certain cancers. Our nanoparticle technology is currently employed in the development of improved drug products such as cancer chemotherapeutics.
PharmaNova: Technology for Better Medicines
« Back to Media
Members of the media wishing to learn more about Pharmanova should contact: Rodney Brown, President. Rodney.Brown@pharmanovaco.com, (585)-413-4721.